CG MedTech
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
CG MedTech makes surgical implants and devices used in orthopaedic and spinal procedures, including spinal fixation systems, fracture-treatment devices, minimally invasive surgical tools, dental implants, and bone-graft biologics, supplied to hospitals and clinics.
It is listed on KOSDAQ, South Korea's tech and small-cap exchange. The company operates two distinct divisions: a medical-devices business and an electric-energy business that supplies electricity meters, heat-energy meters, electric-vehicle charging equipment, and related testing instruments, partly through government-led smart-grid and renewable-energy projects.
Summary is AI-generated and may contain errors · figures from DART filings
CG MedTech expanded into dental implants through the acquisitions of GDS, All Abutment, and Dental Ocean, and into the electric-energy sector through the acquisitions of DM Power and Infinity Works.
CG MedTech in five facts
What does CG MedTech do?
CG MedTech makes surgical implants and devices used in orthopaedic and spinal procedures, including spinal fixation systems, fracture-treatment devices, minimally invasive surgical tools, dental implants, and bone-graft biologics, supplied to hospitals and clinics.
Where is CG MedTech listed and in which sector?
CG MedTech (Korean name: 시지메드텍) trades under KRX code 056090 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is CG MedTech?
Its market capitalisation was US$77.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were CG MedTech's latest annual revenue and operating profit?
For fiscal year 2025, CG MedTech reported revenue of US$35.7M, operating profit of US$2.9M and net income of US$4.9M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 36.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 15
- Trading suspension liftedOct 6
- Report on securities held by executives/major shareholdersSep 11
- Report on large shareholdings (5% rule) (standard)Sep 11
- Trading suspension (share consolidation/split registration)M&A · Sep 7
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
CG MedTech reported consolidated results for FY2025: revenue of US$32M (+36.43% year on year), operating profit of US$2.58M (from a loss a year earlier) and net income of US$4.28M (from a loss a year earlier).
Earnings · Mar 12 - Change of largest shareholderOwnership change · Jan 12